首頁 › 伯基特淋巴瘤 › 賓夕法尼亞州 › Pittsburgh
Pittsburgh, PA 的 伯基特淋巴瘤 臨床試驗
6 項針對 伯基特淋巴瘤 的研究正在 Pittsburgh(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
招募中2 期
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
招募中2 期
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
招募中2 期
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
招募中3 期
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
招募中1/2 期
- UPMC Hillman Cancer Center, Pittsburgh
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
招募中2 期
- AHN Cancer Institute - West Penn Hospital, Pittsburgh
其他城市的 伯基特淋巴瘤 試驗
- Houston, TX21 項研究
- Philadelphia, PA16 項研究
- Milwaukee, WI16 項研究
- Chicago, IL15 項研究
- Cincinnati, OH13 項研究
- New York City, NY13 項研究
- Atlanta, GA12 項研究
- Aurora, CO11 項研究
- Seattle, WA11 項研究
- Durham, NC10 項研究
- Boston, MA10 項研究
- Kansas City, MO10 項研究
Pittsburgh 的其他研究
- 非小細胞肺癌48 項研究
- 癌症(所有類型)41 項研究
- 乳癌39 項研究
- 大腸直腸癌32 項研究
- 轉移性癌症31 項研究
- 黑色素瘤31 項研究
- 卵巢癌30 項研究
- 子宮內膜癌23 項研究
- 前列腺癌23 項研究
- 肺癌23 項研究
- 頭頸部鱗狀細胞癌22 項研究
- 中風22 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。